HomeAI · summaries
Storia in 5 fonti
Vera's IgAN approval kicks off competition with Otsuka
Vera Therapeutics' atacicept wins FDA accelerated approval for IgAN, entering a competitive market alongside Otsuka's Voyxact with a dual APRIL/BAFF mechanism.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
What's Going on with Vera Therapeutics Stock on Monday? - Vera Therapeutics (NASDAQ:VERA)
Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors weigh trial data and competition from Novartis.
- ·
healio.com
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to…
